Anna Skwarska
Overview
Explore the profile of Anna Skwarska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
3096
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DiNardo C, Verma D, Baran N, Bhagat T, Skwarska A, Lodi A, et al.
Nat Cancer
. 2024 Sep;
5(10):1515-1533.
PMID: 39300320
Malignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine...
2.
Chakraborty S, Morganti C, Pena B, Zhang H, Verma D, Zaldana K, et al.
bioRxiv
. 2024 Aug;
PMID: 39211137
Statement Of Purpose: Five-year survival from AML is dismal at 30%. Our prior research demonstrated STAT3 over-expression in AML HSPC's to be associated with inferior survival. We now explore STAT3...
3.
Niemira M, Bielska A, Chwialkowska K, Raczkowska J, Skwarska A, Erol A, et al.
Front Mol Biosci
. 2024 Mar;
11:1368372.
PMID: 38455766
According to the fifth edition of the WHO Classification of Tumours of the Central Nervous System (CNS) published in 2021, grade 4 gliomas classification includes IDH-mutant astrocytomas and wild-type IDH...
4.
Niemira M, Erol A, Bielska A, Zeller A, Skwarska A, Chwialkowska K, et al.
Sci Rep
. 2023 Nov;
13(1):19287.
PMID: 37935712
Epithelial ovarian cancer (EOC) is one of the leading cancers in women, with high-grade serous ovarian cancer (HGSOC) being the most common and lethal subtype of this disease. A vast...
5.
Skwarska A, Konopleva M
Cancer Res
. 2023 Oct;
83(21):3501-3503.
PMID: 37824434
Restoring apoptotic cell death is a critical goal for cancer therapy. One of the primary mechanisms by which cancer cells evade death and maintain survival in the face of stress...
6.
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, et al.
Res Sq
. 2023 Mar;
PMID: 36865338
Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate...
7.
Beird H, Yin C, Khoury J, Pierce S, Abbas H, Zhao L, et al.
Blood Adv
. 2023 Jan;
7(10):2000-2003.
PMID: 36689729
No abstract available.
8.
Bielska A, Niemira M, Bauer W, Sidorkiewicz I, Szalkowska A, Skwarska A, et al.
Front Endocrinol (Lausanne)
. 2022 Jun;
13:888948.
PMID: 35663309
The increasing morbidity and mortality of type 2 diabetic mellitus (T2DM) patients with ischemic heart disease (IHD) highlight an urgent need to identify early biomarkers, which would help to predict...
9.
Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, et al.
Nat Commun
. 2022 May;
13(1):2801.
PMID: 35589701
T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 that facilitate glutamine oxidation. Here we identify oxidative phosphorylation (OxPhos) as a critical pathway for leukemia cell...
10.
Cai T, Gouble A, Black K, Skwarska A, Naqvi A, Taylor D, et al.
Nat Commun
. 2022 Apr;
13(1):2228.
PMID: 35484100
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that...